Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease

Table 3 Characteristics of 20 patients with EGFR-TKIs induced ILD

No	Age	Sex	Histological type	Smoking history	Stage	PS	Prior CT	Prior RT	Preexisting fibrosis	Preexisting emphysema	*EGFR*mutation	Type of EGFR-TKI	Length of EGFR-TKI	CT findings	Prognosis
1	68	M	SCC	Ex	IIIB	1	1	No	No	Yes	N.E.	Gefitinib	11	COP/EP	Alive
2	80	M	SCC	Never	Rec	2	1	No	Yes	Yes	Wild	Gefitinib	17	COP/EP	Alive
3	70	F	SCC	Never	IIIA	1	1	Yes	No	No	N.E.	Gefitinib	24	HP	Alive
4	60	M	ADC	Never	IIIB	1	1	No	No	No	N.E.	Gefitinib	35	COP/EP	Alive
5	68	F	ADC	Ex	Rec	1	2	No	No	No	Wild	Gefitinib	16	AIP	Dead
6	60	M	ADC	Current	IIIB	1	2	No	No	Yes	N.E.	Gefitinib	26	COP/EP	Alive
7	57	M	ADC	Never	Rec	0	3	No	No	No	L858R	Gefitinib	51	COP/EP	Alive
8	73	M	ADC	Current	IV	4	0	No	Yes	Yes	N.E.	Gefitinib	13	AIP	Dead
9	65	F	ADC	Never	IV	2	3	No	No	No	N.E.	Gefitinib	38	HP	Dead
10	69	F	ADC	Never	IIIB	2	1	No	Yes	No	N.E.	Gefitinib	14	AIP	Dead
11	84	F	ADC	Ex	IIIB	4	0	No	Yes	No	Wild	Gefitinib	16	AIP	Dead
12	63	F	SCC	Never	IV	1	1	No	Yes	No	N.E.	Gefitinib	50	COP/EP	Dead
13	67	F	ADC	Never	Rec	0	1	No	No	No	Deletion	Gefitinib	48	HP	Alive
14	60	M	ADC	Current	IV	4	0	No	Yes	Yes	L858R	Gefitinib	17	HP	Dead
15	55	M	ADC	Ex	IV	3	4	No	No	No	L858R	Gefitinib	47	COP/EP	Dead
16	69	M	ADC	Current	IV	3	1	No	Yes	No	Wild	Erlotinib	14	AIP	Dead
17	56	M	SCC	Current	Rec	0	1	No	Yes	Yes	Wild	Erlotinib	21	COP/EP	Alive
18	59	M	ADC	Ex	Rec	1	2	No	Yes	No	Wild	Erlotinib	5	HP	Alive
19	66	M	ADC	Current	IIIB	0	0	No	No	No	L858R	Gefitinib	17	COP/EP	Alive
20	64	F	ADC	Never	Rec	1	1	No	No	No	L858R	Erlotinib	31	HP	Alive

Abbreviations: ADC, Adenocarcinoma; SCC, Squamous cell carcinoma; Rec, Recurrence after the surgery; CT, Chemotherapy; RT, Radiation therapy; N.E, Not evaluated; COP/EP, Cryptogenic organizing pneumonia/Eosinophilic pneumonia; HP, Hypersensitivity pneumonitis; DAD, Diffuse alveolar damage.

ISSN: 1465-993X